Premium
Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B‐cell malignancies: Results of a phase I study
Author(s) -
Hamlin Paul A.,
Flinn Ian W.,
WagnerJohnston Nina,
Burger Jan A.,
Coffey Greg P.,
Conley Pamela B.,
Michelson Glenn,
Leeds Janet M.,
Der Kenneth,
Kim Yvonne,
SabalvaroTorres Alice,
Birrell Matt,
Pandey Anjali,
Curnutte John T.,
Patel Manish R.
Publication year - 2019
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.25387
Subject(s) - syk , refractory (planetary science) , medicine , oncology , cancer research , receptor , tyrosine kinase , biology , astrobiology